Risk factors for cardiovascular disease and mortality events in adults with type 2 diabetes - a 10-year follow-up: Tehran Lipid and Glucose Study.

Afsharian, Sheila; Akbarpour, Samaneh; Abdi, Hengameh; Sheikholeslami, Farhad; Moeini, Ali Siamak; Khalili, Davood; Momenan, Amir Abbas; Azizi, Fereidoun; Hadaegh, Farzad

<bold>Background: </bold>To identify risk factors for cardiovascular disease (CVD) and mortality events in patients with type 2 diabetes and to calculate their population attributable fraction among a representative Iranian population.<bold>Methods: </bold>A total of 1198 patients with type 2 diabetes (504 men and 694 women), aged ≥30 years, without prevalent CVD, with a median follow-up of 10 years were included in current study. To examine the association between risk factors and their outcomes, multivariate sex-adjusted Cox proportional hazard regression models were used.<bold>Results: </bold>During the study, 281 and 172 participants experienced CVD and all-cause mortality events, respectively. Regarding CVD events, fasting plasma glucose (FPG) level of 7.22-<10 mmol/L [hazard ratio (HR): 1.46, 95% CI 1.12-1.96], FPG level ≥10 mmol/L (HR 2.04, 1.53-2.72), hypertension (HR 1.65, 1.28-2.13), hypercholesterolaemia (HR 1.96, 1.40-2.75) and high waist to hip ratio (HR 1.30, 0.99-1.70; p = 0.051) were significant predictors, and corresponding population attributable fractions were 9.76, 17.84, 23.26, 41.63 and 14.76%, respectively. Considering all-cause mortality events, hypertension (HR 1.70, 1.23-2.36), FPG level ≥10 mmol/L (HR 2.31, 1.55-3.20) and smoking (HR 1.45, 1.03-2.04) were significant predictors, and corresponding population attributable fractions were 25.81, 20.88 and 11.18%, respectively. Meanwhile, being overweight or obese was associated with lower all-cause and CVD mortality events.<bold>Conclusions: </bold>Among modifiable risk factors in patients with type 2 diabetes, hypercholesterolaemia and central adiposity for CVD, smoking for mortality events and hypertension and poor glycaemic control for both outcomes need to be paid most attention by healthcare professionals. Copyright © 2016 John Wiley & Sons, Ltd.

IRAN; BLOOD sugar analysis; CARDIOVASCULAR disease related mortality; TYPE 2 diabetes complications; HYPERTENSION epidemiology; OBESITY complications; CARDIOVASCULAR diseases; GLYCOSYLATED hemoglobin; HYPERGLYCEMIA; HYPERTENSION; LONGITUDINAL method; TYPE 2 diabetes; PROGNOSIS; SMOKING; SURVIVAL; TIME; CROSS-sectional method

Diabetes/Metabolism Research & Reviews, 2016, Vol 32, Issue 6, p596

1520-7552

Academic Journal

10.1002/dmrr.2776